Farmas USA

Akebia Secures $100 Million Non-Dilutive Term Loan Financing; Reports Third Quarter 2019 Financial Results

• Funding expected to extend Company’s cash runway into 2021, well past its expected topline data readouts for global Phase 3 studies for vadadustat;
• MTPC’s positive Phase 3 data show vadadustat’s effect on hemoglobin was sustained through to 52 weeks;
• Auryxia ® (ferric citrate) revenue increases to $30.0 million for Q3’FY19, up 13% from Q3’FY18; and,
• Company hosts call to discuss financial results and recent business highlights
  
  Eso si, muy optimistas:
  
  “We have a tremendous amount of confidence in the program that we've designed for vadadustat and believe we are positioned well for clinical, regulatory and commercial success. We expect vadadustat to be the first drug of the HIF class to deliver clear data that directly compares its outcomes to the current standard of care in both dialysis and non-dialysis patients for the treatment of anemia due to CKD. We believe these data will be highly informative for physicians, patients and payers as they make important decisions about patient care, and a key consideration when differentiating between HIFs in the class.”

BofA/Merrill Lynch initiated Exelixis buy and target $22

It is initiated with a Buy rating and $22 price target at Merrill Lynch today.  Merrill's analyst expects 'the shares to rebound following a difficult few quarters ahead of ahead of the Phase 3 catalysts for lead drug Cabometyx. He sees a better entry point following the stock's recent selloff'.